October 05, 2020
Reimbursement request list for companion diagnostics and personalized medicine updated in Belgium
In September 2020, the list of companion diagnostic tests, which are evaluated for reimbursement, was updated. INAMI has a specific reimbursement framework for companion diagnostic tests. INAMI Nomenclature codes from Article 33ter can only be reimbursed in relation to specific biomarker tests and drugs from Chapter VIII of the reimbursable pharmaceutical specialties (Royal Decree of February 1, 2018).

The updated list of molecular companion diagnostics (accompanied by appropriate active ingredient) for which a reimbursement application has been made (with the month of the application) is presented below:

  • ALK - Lorlatinib (August 2019)
  • FLT3-TKD and FLT3-ITD - Gilteritinib (October 2019)
  • NTRK - Larotrectinib (October 2019)
  • BCR/ABL1 - Dasatinib (November 2019)
  • TP53 and 17p deletion - Venetoclax + Obinutuzumab (April 2020)
  • BRAF V600 - Trametinib + Dabrafenib (June 2020)
  • ALK - Brigatinib (June 2020)
  • PIK3CA - Alpelisib (July 2020)
See the full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Subscribe to newsletter
Subscribe to our newsletter to get regular updates from us on the changes of reimbursement systems (>100 reimbursement stakeholders in 12 EU countries)